PhoreMost, a biopharmaceutical leader, has secured an additional $12 million in Series B financing, raising its total to over $50 million.
This funding boost, led by Parkwalk Advisors, supports its mission to advance cancer treatments through innovative degrader programs targeting oncology and inflammation.
PhoreMost’s work in drug discovery has positioned it at the forefront of identifying proteins once considered undruggable. Using its SITESEEKER platform, substantial progress is being made, especially in oncology and inflammatory diseases. These efforts focus on degrading disease-causing proteins, potentially transforming treatments for conditions with limited options.
With the launch of the GlueSEEKER platform, PhoreMost expands its scientific capabilities. This advanced tool discovers molecular glue degraders that stabilise protein-protein interactions, targeting diseases such as oncology and neurodegeneration.
GlueSEEKER enhances PhoreMost’s established SITESEEKER platform, integrating computational and phenotypic screening to identify new therapeutic targets.
Partnerships with various pharmaceutical companies are bolstered by GlueSEEKER, strengthening PhoreMost’s role as a leader in targeted protein degradation therapies.
Alastair Kilgour applauds this progress, emphasising the potential for transformative patient outcomes and inspiring future drug discovery.
PhoreMost’s collaborations are integral to advancing its position in the therapeutic landscape, paving the way for novel treatment developments.
PhoreMost remains committed to its mission to ‘drug the undruggable’, continuously seeking solutions for high-value therapeutic areas.
The allosteric PLK1 program for brain cancer is set to enter clinical phases, driving potential breakthroughs in the near future.
The company’s research advancements promise significant contributions to drug discovery, offering new hope for patients with currently untreatable conditions.
The new $12 million funding amplifies PhoreMost’s already robust pipeline, enhancing its potential to address high-value therapeutic needs in cancer treatment.
This investment strengthens PhoreMost’s research and development, solidifying its leadership position within the next-generation degrader field.
The financial backing allows for the expansion of critical platforms like GlueSEEKER, necessary for the company’s ambitious research goals.
PhoreMost’s strategic advancements and significant financial backing underscore its pivotal role in the future of cancer treatment.
With ongoing research and powerful collaborations, the company is poised to make remarkable strides in offering solutions for previously untreatable diseases.
The combination of pioneering science and robust funding positions PhoreMost as a key player in revolutionising cancer treatment. Its determination to ‘drug the undruggable’ remains unwavering, promising new therapeutic pathways for patients worldwide.
